Table 4.
Age | Race | Sex | diagnosis | CYP2C19 | Adherence | N meds | Max dose | Cont | Omep | |
---|---|---|---|---|---|---|---|---|---|---|
Sum of side effects | 0.03 | 0.0496 | 0.014 | 3.30E-18 | 1.50E-08 | |||||
Activation (sum of irritability, insomnia, hyperactivity, impulsivity) | 0.019 | 0.037 | 3.26E-11 | 5.20E-07 | ||||||
Drowsiness | 0.04 | 0.001 | 1.40E-05 | 7.80E-05 | ||||||
Irritability | 5.60E-05 | 0.004 | ||||||||
Insomnia | 0.04 | 0.0001 | 5.10E-06 | |||||||
Impulsivity | 0.04 | 0.045 | 0.002 | 0.03 | ||||||
Hyperactivity | 2.10E-06 | 0.003 | ||||||||
Headache | 1.10E-05 | 0.04 | ||||||||
Nausea | 0.03 | 0.008 | 1.10E-06 | 0.038 | ||||||
GI Toxicity | 1.20E-05 | 0.03 | 0.009 | |||||||
Weight Gain | 0.04 | 0.02 | 4.10E-05 | 0.0008 | ||||||
Hospitalization days | 0.04 | 0.01 | 1.50E-13 | 4.20E-07 | ||||||
Response | 0.01 | 0.046 | 0.026 | 0.006 | ||||||
Response dose | 0.03 | 0.003 | 7.00E-04 | NA | 0.008 | |||||
N, number. Meds, psychotropic medications. Max, maximum. Cont, concomitant oral contraceptives. Omep, concomitant omeprazole. GI, gastrointestinal.